Federal regulators have added a genuinely new kind of weapon to the multiple myeloma arsenal. On August 13, 2026, the Food ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Multiple myeloma is a blood cancer affecting plasma cells, causing abnormal antibody production and bone damage. Diagnosis involves blood tests, bone marrow biopsy, imaging, and genetic analysis to ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled "NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma." Researchers Andrea ...

Swarup Kumar, MD, of UConn Health, says iberdomide plus dara-dex fills a niche for relapsed disease in patients who lack access to CAR T or bispecifics. The FDA’s August 13 accelerated approval of ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...

Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Diagnosis involves blood, urine, and bone marrow tests, with ...

The FDA has granted accelerated approval to iberdomide (ZENBEXUS), a first‑in‑class CELMoD (a newer type of targeted ...